Abstract | RATIONALE: DPP-4 (dipeptidyl peptidase-4) inhibitors have increased the risk of heart failure events in both randomized clinical trials and observational studies, but the mechanisms that underlie their deleterious effect remain to be elucidated. Previous work has implicated a role of these drugs to promote cardiac fibrosis. OBJECTIVE: This article postulates that DPP-4 inhibitors increase the risk of heart failure events by activating the sympathetic nervous system to stimulate cardiomyocyte cell death, and it crystallizes the findings from both experimental studies and clinical trials that support the hypothesis. METHODS AND RESULTS: CONCLUSIONS:
|
Authors | Milton Packer |
Journal | Circulation research
(Circ Res)
Vol. 122
Issue 7
Pg. 928-932
(03 30 2018)
ISSN: 1524-4571 [Electronic] United States |
PMID | 29436388
(Publication Type: Journal Article, Review)
|
Copyright | © 2018 The Authors. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
|
Topics |
- Adrenergic Neurons
(drug effects)
- Animals
- Cardiotoxicity
- Clinical Trials as Topic
- Dipeptidyl-Peptidase IV Inhibitors
(pharmacology, toxicity)
- Heart Failure
(etiology)
- Humans
- Hypoglycemic Agents
(pharmacology, toxicity)
- Sympathetic Nervous System
(cytology, drug effects)
|